Doctor-led medical care · Ubi, Singapore 6844 1528 WhatsApp
Medications

Gabapentinoids and Weight Gain

Gabapentin and pregabalin, widely used for nerve pain, epilepsy and anxiety, cause weight gain in a substantial minority of users, and the risk rises with dose.

Plain English

Patient-Friendly Explanation

Gabapentin and pregabalin are closely related medicines, known together as the gabapentinoids. They are prescribed for nerve pain, shingles pain, fibromyalgia, epilepsy and sometimes anxiety, and they are used quite often in people whose nerve pain comes from diabetes, which is common alongside excess weight. They cause two separate things that both push the scale up. The first is fluid: these medicines commonly make ankles and legs swell, and fluid weighs a lot. The second is appetite, which appears to increase in some people. The result is weight that creeps up over months and is easy to blame on something else. In the pregabalin trials, about 9 in 100 patients gained at least 7 per cent of their starting body weight, compared with 2 in 100 on placebo, and average gains of 2 to 4 kg have been reported over one to two years, with a smaller group gaining much more. The risk is clearly dose-related and rises above 300 mg a day of pregabalin. Not everyone is affected, and about 15 per cent see no change at all. If you take one of these medicines and your weight has risen, the useful questions are whether the dose can be reduced, whether a different pain medicine would work as well, and whether there is ankle or leg swelling that needs checking, because fluid and fat are different problems that need different answers. Do not stop these medicines abruptly, as that can cause seizures or withdrawal symptoms.

Medical

Clinical Definition

Gabapentinoids bind the alpha-2-delta subunit of voltage-gated calcium channels and reduce release of excitatory neurotransmitters, which underlies their use in neuropathic pain, epilepsy and generalised anxiety. The weight-gain mechanism is incompletely characterised but combines peripheral oedema from fluid retention with a probable central effect on appetite and satiety signalling. In the pregabalin randomised controlled programme, 9 per cent of treated patients gained 7 per cent or more of baseline body weight against 2 per cent of those on placebo. In a 20-week phase 2 study of 420 patients with painful diabetic peripheral neuropathy, pregabalin 300 mg daily produced a mean weight change of +2.65 kg (2 SE 0.92) over the 12-week maintenance phase against -0.55 kg (0.72) on placebo; 15 per cent versus 3 per cent gained at least 7 per cent of body weight and peripheral oedema affected 17 per cent versus 4 per cent. Long-term follow-up data report mean gains of about 5.2 kg after two or more years of pregabalin, and pooled gabapentin trial data report weight gain as an adverse event in approximately 16 per cent of patients against 4 per cent on placebo. Incidence is dose-related and rises sharply above 300 mg per day of pregabalin; pregabalin is generally associated with more gain than gabapentin, and the effect appears more pronounced in diabetic neuropathy than in fibromyalgia or epilepsy. Because oedema and weight gain can be early signs of fluid overload, a rapid rise in weight accompanied by new breathlessness or leg swelling in a patient taking a gabapentinoid deserves assessment of cardiac and renal function, and dose reduction or substitution rather than dietary advice alone. Abrupt withdrawal must be avoided.

Key Insight

Why It Matters

Gabapentinoid weight gain is dose-related and partly fluid, so the productive step is a medication review rather than a stricter diet.

Sources

Reviewed against standard medical references.

Medically reviewed by

Dr Joseph Wang

Family Physician & Registered Acupuncturist, Accord Medical Clinic. MBBS (NUS), Graduate Diploma in Family Medicine (NUS), Graduate Diploma in Acupuncture (Singapore College of TCM).

Last reviewed: September 2026

This page is general health education, not medical advice. Whether any treatment is appropriate for you is a decision made in consultation after assessment.

WhatsApp
Call WhatsApp Book now